Filtered by vendor Selinc
Subscriptions
Filtered by product Sel-451
Subscriptions
Total
5 CVE
CVE | Vendors | Products | Updated | CVSS v3.1 |
---|---|---|---|---|
CVE-2023-34389 | 1 Selinc | 2 Sel-451, Sel-451 Firmware | 2024-12-02 | 4.5 Medium |
An allocation of resources without limits or throttling vulnerability in the Schweitzer Engineering Laboratories SEL-451 could allow a remote authenticated attacker to make the system unavailable for an indefinite amount of time. See product Instruction Manual Appendix A dated 20230830 for more details. | ||||
CVE-2023-34390 | 1 Selinc | 2 Sel-451, Sel-451 Firmware | 2024-11-21 | 4.5 Medium |
An input validation vulnerability in the Schweitzer Engineering Laboratories SEL-451 could allow a remote authenticated attacker to create a denial of service against the system and locking out services. See product Instruction Manual Appendix A dated 20230830 for more details. | ||||
CVE-2023-34388 | 1 Selinc | 2 Sel-451, Sel-451 Firmware | 2024-11-21 | 6.5 Medium |
An Improper Authentication vulnerability in the Schweitzer Engineering Laboratories SEL-451 could allow a remote unauthenticated attacker to potentially perform session hijacking attack and bypass authentication. See product Instruction Manual Appendix A dated 20230830 for more details. | ||||
CVE-2023-31177 | 1 Selinc | 2 Sel-451, Sel-451 Firmware | 2024-11-21 | 4.3 Medium |
An Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') in the Schweitzer Engineering Laboratories SEL-451 could allow an attacker to craft a link that could execute arbitrary code on a victim's system. See product Instruction Manual Appendix A dated 20230830 for more details. | ||||
CVE-2023-31176 | 1 Selinc | 2 Sel-451, Sel-451 Firmware | 2024-11-21 | 7.5 High |
An Insufficient Entropy vulnerability in the Schweitzer Engineering Laboratories SEL-451 could allow an unauthenticated remote attacker to brute-force session tokens and bypass authentication. See product Instruction Manual Appendix A dated 20230830 for more details. |
Page 1 of 1.